William Tap

William Tap led the pivotal clinical trials of pexidartinib, the first FDA-approved CSF1R inhibitor, demonstrating dramatic responses in tenosynovial giant cell tumors and establishing proof-of-concept for therapeutic macrophage depletion in cancer. His ENLIVEN trial showed that CSF1R inhibition can produce durable responses by depleting tumor-promoting macrophages. He has advanced combinations of CSF1R inhibitors with checkpoint immunotherapy in solid tumors. His clinical research has validated macrophage targeting as a therapeutic strategy in oncology.